The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

256

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

October 30, 2024

Study Completion Date

February 28, 2025

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

IDegLira

The participants in this group will be switched to IDegLira once daily injection therapy.

DRUG

Premixed insulin

The participants in this group will be have optimized premixed insulin regimen.

All Listed Sponsors

lead

Peking University People's Hospital

OTHER